Circ Cardiovasc Interv

Slides:

Advertisements

Similar presentations

Kenneth W. Mahaffey Daniel M. Wojdyla Stefan K. James Hugo A. Katus Steen Husted Gabriel Steg Christopher P. Cannon Richard C. Becker Claes Held Nardev.

Advertisements

Conclusion The fair agreement between both the sites and the ACL and the sites and CEC emphasizes the need to review all potential events. There is only.

Kenneth W. Mahaffey, Zhen Huang, Pierluigi Tricoci, Frans Van de Werf, Harvey D. White, Paul W. Armstrong, Claes Held, Sergio Leonardi, Philip E. Aylward,

NSTE Acute Coronary Syndromes

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduced-Function CYP2C19 Genotype and Risk of Adverse.

Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Correlates of Drug-Eluting Stent Thrombosis.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

Copyright © 2006 American Medical Association. All rights reserved.

Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.

Outcomes of a Pharmacoinvasive Strategy for Successful Versus Failed Fibrinolysis and Primary Percutaneous Intervention in Acute Myocardial Infarction.

Copyright © 2013 American Medical Association. All rights reserved.

Driving Times and Distances to Hospitals With Percutaneous Coronary Intervention in the United States by Brahmajee K. Nallamothu, Eric R. Bates, Yongfei.

Long-term clinical outcome of elderly patients with acute coronary syndrome treated with early percutaneous coronary intervention: Insights from the BASE.

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype status. Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype.

Spontaneous Coronary Artery Dissection

Arterioscler Thromb Vasc Biol

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Sex-Related Differences in Fractional Flow Reserve–Guided Treatment

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Value-Based Hypothesis Testing for Cardiac Device Clinical Trials

Circ Cardiovasc Qual Outcomes

Optima DES system: The stent has multiple grooves (reservoirs) on its abluminal surface into which the drug is loaded. Optima DES system: The stent has.

Circ Cardiovasc Interv

Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.

Site Selection and Performance in Clinical Trials

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

Circ Cardiovasc Qual Outcomes

Contribution of Stroke to the Cochrane Stroke Group Trials Register

Attenuation of Rebound Ischemia After Discontinuation of Heparin Therapy by Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Acute Coronary.

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Catheter-Based Treatment of Coronary Artery Disease

Masaya Koshizaka, MD, PhD, Renato D. Lopes, MD, PhD, MHS, L

Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)

Early Invasive Versus Initial Conservative Strategies for Women with Non–ST-Elevation Acute Coronary Syndromes: A Nationwide Analysis Islam Y. Elgendy,

Eric L. Eisenstein, DBA, Darren K. McGuire, MD, MHS, Manjushri V

Nat. Rev. Cardiol. doi: /nrcardio

Differences in the Clinical Features and Outcomes in African Americans and Whites with Myocardial Infarction Rajendra H. Mehta, MD, MS, David Marks,

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Efficacy and Safety of Thrombin-Receptor Antagonist (Atopaxar and Vorapaxar) in Patients with Acute Coronary Syndrome or Coronary Artery Disease—A Meta-Analysis.

Why surgery won the SYNTAX trial and why it matters

Tornado diagram of one-way deterministic sensitivity analysis.

John A. Bittl et al. JACC 2016;68:

Fig. 3. Determining factors of the proportion of class C in the hospital. (A) Relationship between the proportion of class C cases and the number of PCIs.

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Renato D. Lopes, MD, PhD on behalf of the.

(A) Meta-analysis of repeat revascularisation in randomised trials.

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

International Journal of Cardiology

Giuseppe Gargiulo et al. JACC 2018;71:

Baseline Q Waves and Time From Symptom Onset to ST-segment Elevation Myocardial Infarction: Insights From PLATO on the Influence of Sex Naji Kholaif,

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Pamela E. Scott et al. JACC 2018;71:

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision.

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Sex Differences in the Management and 5-Year Outcome of Young Patients (

Presentation transcript:

Circ Cardiovasc Interv Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis by Christopher J. Popma, Shi Sheng, Serge Korjian, Yazan Daaboul, Gerald Chi, Pierluigi Tricoci, Zhen Huang, David J. Moliterno, Harvey D. White, Frans Van de Werf, Robert A. Harrington, Lars Wallentin, Claes Held, Paul W. Armstrong, Philip E. Aylward, John Strony, Kenneth W. Mahaffey, and C. Michael Gibson Circ Cardiovasc Interv Volume 9(5):e003114 May 9, 2016 Copyright © American Heart Association, Inc. All rights reserved.

Consort diagram. Consort diagram. ARC indicates Academic Research Consortium; CEC, clinical event committee; eCRF, electronic case report form; LI, local investigator; MI, myocardial infarction; PCI, percutaneous coronary intervention; and TRACER, Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome. Christopher J. Popma et al. Circ Cardiovasc Interv. 2016;9:e003114 Copyright © American Heart Association, Inc. All rights reserved.

Assessment of stent thrombosis by sites, CEC, and angiographic core laboratory. Assessment of stent thrombosis by sites, CEC, and angiographic core laboratory. ACL indicates angiographic core laboratory; CEC, clinical event committee; CI, confidence interval; and LI, local investigator. Christopher J. Popma et al. Circ Cardiovasc Interv. 2016;9:e003114 Copyright © American Heart Association, Inc. All rights reserved.